-
Diversity, Equity, and Inclusion Guidelines Still Not Optimal for HIV-Positive Patients
Clinical Research News | While randomized clinical trials (RCTs) have rightly long been considered the gold standard for establishing the safety and efficacy of new medications, their strict inclusion and exclusion criteria narrow participant types. For example, RCTs tend to exclude certain patient sub-groups, especially those with specific comorbidities. The scientific rationale behind these practices results from a desire to assess the benefit/risk ratio in a stepwise fashion, starting with the most homogenous population to more heterogeneous ones as development of a therapeutic progresses.
Dec 6, 2024
-
PAN Foundation Taking Health Literacy Approach to Improve Trial Access
Clinical Research News | The PAN Foundation, a nonprofit that has been providing financial assistance to patients with life-threatening, chronic, and rare diseases since 2004, has just launched an Opening Doors to Clinical Trials initiative aiming to improve equitable access to studies. Assistance is now freely available to people everywhere in the form of basic education about trials, a user-friendly trial finder tool, and a live person who can answer questions and direct them to needed resources.
Dec 4, 2024
-
Diversity Begins at the Bench: Walking Back a Patient-Centered View of Trial Design
Clinical Research News | At the SCOPE Europe conference held in Barcelona last month, clinical trials leaders highlighted transformative shifts toward diversity, inclusion, and patient engagement in study designs. Liz Bristow, director of patient recruitment and retention at AstraZeneca, and Jodie Allen, global senior director of clinical trial diversity at AstraZeneca UK, outlined key advancements and persistent challenges in achieving equitable patient representation across clinical trials.
Dec 3, 2024
-
Follow the Money: Alpha-9 to Advance Radiopharmaceuticals, Dermatitis, Crohn’s Disease Studies, More
Clinical Research News | Alpha-9 funds targeted radiopharmaceuticals; Evommune pursues chronic urticaria and atopic dermatitis; Agomab Therapeutics advances lead candidate in Crohn’s disease (FSCD); and more.
Nov 26, 2024
-
GeneDX Novel Data Visualization Tool, New Landmark Parkinson’s Initiative, More
Clinical Research News | GeneDx announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data—powered by GeneDx’s database—to improve all stages of drug development; Critical Path Institute announced a landmark initiative, Gender Equitable Medicines for Parkinson's Disease, dedicated to globally advancing actionable research on how Parkinson's disease uniquely impacts women and individuals across the sex and gender spectrum; and more.
Nov 25, 2024
-
Trends in Biosimilars
Clinical Research News | The global biosimilars market is experiencing substantial growth, valued at $29.45 billion in 2023, it is projected to reach $150.3 billion by 2033 (CAGR of 17.7%). This upward trajectory is primarily driven by the ability of biosimilars to offer safe, clinically effective, and cost-effective alternatives to reference biologics, expanding patient access to treatments for the ever-rising number of chronic and severe illnesses.
Nov 22, 2024